Business Context and Reporting Period
Company: Adaptive Biotechnologies Corporation (ADPT)
Filing Type: Form 8-K (Current Report)
Date of Report: June 15, 2026 (Event Date: June 22, 2026)
Context: The Company announced the issuance of $345 million in 0% Convertible Senior Notes due 2031 and the simultaneous repayment of a prior revenue interest agreement with OrbiMed.
Key Financial Metrics and Capital Structure
- Debt Issuance: $345 million aggregate principal amount of 0% Convertible Senior Notes due 2031 (includes $45 million from full exercise of initial purchasers' option).
- Net Proceeds: Approximately $334.5 million after discounts, commissions, and estimated expenses.
- Use of Proceeds:
- $156.9 million: Repayment of OrbiMed Purchase Agreement obligations.
- $25.6 million: Cost of capped call transactions.
- $25.0 million: Repurchase of 1,451,800 shares of common stock.
- Remainder: General corporate purposes and MRD business initiatives.
- Conversion Terms: Initial conversion rate of 41.4800 shares per $1,000 principal (approx. $24.11 per share), representing a 40.0% premium over the June 16, 2026 stock price of $17.22.
- Maximum Dilution: Up to 20,034,840 shares of common stock may be issued upon conversion.
- Interest: Notes bear 0% regular interest; principal does not accrete.
Material Changes vs. Prior Period
This filing represents a significant restructuring of the Company's capital base rather than a period-over-period operating comparison.
- Debt Reduction: The Company fully repaid its obligations under the OrbiMed Purchase Agreement (originally $124.4 million received in 2022), eliminating a revenue interest liability that required quarterly payments of 5% of GAAP revenue.
- Liquidity Increase: Net cash inflow of approximately $334.5 million from the new offering, partially offset by immediate debt repayment and stock buybacks.
- Equity Action: Immediate reduction of outstanding shares by 1,451,800 via private repurchase using offering proceeds.
Outlook, Risks, and Contingencies
- Capped Call Transactions: The Company entered into capped call transactions with a cap price of $34.44 per share (100% premium over June 16 price) to offset potential dilution from the Notes. These are separate from the Notes and do not affect noteholder rights.
- Redemption Rights: The Company may redeem the Notes on or after July 1, 2029, if the stock price exceeds 130% of the conversion price for a specified period.
- Events of Default: Includes payment defaults, failure to convert, bankruptcy, and defaults on other indebtedness of at least $50 million. Bankruptcy events trigger immediate acceleration of all Notes.
- Future Obligations: The Notes mature on July 1, 2031, unless converted or redeemed earlier. The Company retains the option to settle conversions in cash, stock, or a combination.
Investor Verification Checklist
- Verify the final settlement of the OrbiMed repayment ($156.9 million) and confirmation that the 5% revenue interest obligation is fully extinguished.
- Review the specific terms of the Capped Call Transactions (Exhibit 10.1) to understand the mechanics of dilution protection and the $34.44 cap price.
- Monitor the Company's cash balance post-transaction to assess liquidity for general corporate purposes and MRD initiatives.
- Track the stock price relative to the $24.11 conversion price and $34.44 cap price to evaluate conversion likelihood and redemption triggers.
- Confirm the impact of the 1,451,800 share repurchase on the fully diluted share count.